EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The prevention and management of chronic kidney disease among patients with metabolic syndrome

Doreen Zhu, Parminder K Judge, Christoph Wanner, Richard Haynes, William G Herrington

Kidney International · 2025-05 · 107 (5) · 816-824

DOI: 10.1016/j.kint.2024.12.021 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Kidney International, 2025-05. Verfasst von Doreen Zhu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Renal Studies Group, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Ox…. Hauptthemen laut MEDLINE: Metabolic Syndrome, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Treatment of patients with chronic kidney disease (CKD) requires implementation of prevention and management strategies that reduce the risk of kidney failure and CKD-associated cardiovascular risk. Metabolic syndrome is characterized by obesity, high blood pressure, dyslipidemia, and hyperglycemia, and it is common among patients with CKD. Large-scale randomized trials have led to significant advances in the management of CKD, with 5 pharmacotherapies now proven to be nephroprotective and/or cardioprotective in certain types of patients. Renin-angiotensin system inhibitors and sodium-glucose cotransporter 2 inhibitors slow kidney disease progression and reduce heart failure complications for most patients with CKD. In addition, statin-based regimens reduce low-density lipoprotein cholesterol and lower the risk of atherosclerotic disease (with no clinically meaningful effect on kidney outcomes). For patients with type 2 diabetes and albuminuric CKD, the nonsteroidal mineralocorticoid receptor antagonist finerenone and the glucagon-like peptide-1 receptor agonist semaglutide also confer cardiorenal benefits, with semaglutide additionally effective at reducing weight. Together, these randomized data strongly suggest that metabolic syndrome mediates some of the cardiorenal risk observed in CKD. Considered separately, the trials help elucidate which components of metabolic syndrome influence the pathophysiology of kidney disease progression and which separately modify risk of atherosclerotic and nonatherosclerotic cardiovascular outcomes. As we predict complementary and different mechanisms of nephroprotection and cardioprotection for these different interventions, it seems logical that they should be deployed together to maximize benefits. Even when combined, however, these therapies are not a cure, so further trials remain important to reduce the residual cardiorenal risks associated with CKD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Metabolic SyndromeRenal Insufficiency, ChronicHumansSodium-Glucose Transporter 2 InhibitorsDisease ProgressionCardiovascular DiseasesMineralocorticoid Receptor AntagonistsRandomized Controlled Trials as TopicHydroxymethylglutaryl-CoA Reductase InhibitorsRisk Factors

Stichwörter der Autor:innen

cardiovascular diseasediabeteslipidsobesityrenin-angiotensin system

Substanzen

Sodium-Glucose Transporter 2 InhibitorsMineralocorticoid Receptor AntagonistsHydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Renal Studies Group, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK; Oxford Kidney Unit, Oxford University Hospitals NHS Foundati…
  • Renal Studies Group, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.

Zitieren

APA

Zhu, D., Judge, P. K., Wanner, C., Haynes, R., & Herrington, W. G. (2025). The prevention and management of chronic kidney disease among patients with metabolic syndrome. Kidney International, 107(5), 816-824. https://doi.org/10.1016/j.kint.2024.12.021

Vancouver

Zhu D, Judge PK, Wanner C, Haynes R, Herrington WG. The prevention and management of chronic kidney disease among patients with metabolic syndrome. Kidney International. 2025;107(5):816-824. doi:10.1016/j.kint.2024.12.021

BibTeX
@article{Zhu2025,
  author = {Zhu, Doreen and Judge, Parminder K and Wanner, Christoph and Haynes, Richard and Herrington, William G},
  title = {The prevention and management of chronic kidney disease among patients with metabolic syndrome},
  journal = {Kidney International},
  year = {2025},
  volume = {107},
  number = {5},
  pages = {816--824},
  doi = {10.1016/j.kint.2024.12.021}
}
Kostenlos starten →